159. 色素性乾皮症
[臨床試験数:5,薬物数:13(DrugBank:4),標的遺伝子数:4,標的パスウェイ数:13

Searched query = "Xeroderma pigmentosum", "XP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04500548
(ClinicalTrials.gov)
February 26, 20214/8/2020Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent, and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant CancersConstitutional Mismatch Repair Deficiency Syndrome;Hematopoietic and Lymphoid Cell Neoplasm;Lynch Syndrome;Recurrent Lymphoma;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Primary Central Nervous System Neoplasm;Refractory Lymphoma;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Primary Central Nervous System Neoplasm;Xeroderma PigmentosumProcedure: Biospecimen Collection;Biological: Ipilimumab;Biological: NivolumabNational Cancer Institute (NCI)NULLNot yet recruiting12 Months25 YearsAll40Phase 1NULL
2EUCTR2010-022968-13-ES
(EUCTR)
22/03/201125/01/2011Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subexpresión del gen xeroderma pigmentosum de clase G (XPG).Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subexpresión del gen xeroderma pigmentosum de clase G (XPG). Cáncer de mama avanzado.
MedDRA version: 13;Level: LLT;Classification code 10006204;Term: Carcinoma de mama
Trade Name: YONDELIS 0,25 mg polvo para concentrado para solución para perfusión
INN or Proposed INN: TRABECTEDINA
Other descriptive name: TRABECTEDINA
Trade Name: YONDELIS 1 mg polvo para concentrado para solución para perfusión
INN or Proposed INN: TRABECTEDINA
Other descriptive name: TRABECTEDINA
PharmaMar S.A. Sociedad UnipersonalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
100Spain
3EUCTR2010-022968-13-BE
(EUCTR)
16/03/201104/01/2011Study of the medicinal product Trabectedin in Patients with AdvancedBreast Carcinoma.Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderma Pigmentosum G Gene (XPG) Advanced Breast Carcinoma
MedDRA version: 14.0;Level: LLT;Classification code 10006204;Term: Breast carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion.
INN or Proposed INN: trabectedine
Trade Name: Yondelis 1 mg powder for concentrate for solution for infusion.
INN or Proposed INN: trabectedine
Pharma Mar, S.A. Sociedad UnipersonalNULLNot RecruitingFemale: yes
Male: yes
100Phase 2Spain;Belgium
4NCT00002811
(ClinicalTrials.gov)
July 19961/11/1999T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma PigmentosumA RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSESPrecancerous ConditionDrug: liposomal T4N5 lotionApplied GeneticsNULLActive, not recruiting2 Years60 YearsBoth30Phase 3United States;Germany;United Kingdom
5NCT00025012
(ClinicalTrials.gov)
June 199111/10/2001Isotretinoin in Preventing Skin CancerUse Of Isotretinion For Prevention Of Skin Cancer In Patients With Xeroderma Pigmentosum Or Nevoid Basal Cell Carcinoma SyndromeMelanoma (Skin);Non-melanomatous Skin CancerDrug: isotretinoinNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NULLCompleted2 YearsN/ABothN/AUnited States